Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

Important Disclosures:

1. Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) has secured a broad strategic provider network agreement in California that opens access to more than 60 million consumers through a single relationship. The deal, effective July 1, 2026, covers primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage channels and automatically renews each year.

This agreement stands out because it connects Rocket Doctor to upstream insurers, employer health plans, and other organizations through one national network partner instead of separate contracts for each line of business. The network already serves more than 700 health plans, over 100,000 employers, and approximately 1.4 million contracted providers, giving Rocket Doctor a broad pathway to participate in the U.S. healthcare market.

Why the California Agreement Matters Now

California represents a critical entry point for telehealth growth because of its size, regulatory clarity on virtual care, and active workers' compensation market. By integrating state-compliant telehealth standards, Rocket Doctor gains a contracted path to reimbursement across multiple payer types, reducing reliance on any single insurance channel.

Company Advantage Through Diversified Access

Unlike traditional payer agreements limited to one type of coverage, this network relationship allows Rocket Doctor to participate in primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage. The structure supports a more stable revenue base as the company scales its physician network in the state.

Key Assets and Near-Term Catalysts

Rocket Doctor AI is expanding its U.S. payer and physician footprint with Florida and Texas identified as additional target markets. Physician capacity is growing, with 22 clinically active U.S. physicians already onboarded and 33 more in credentialing. Completed U.S. patient visits rose from 86 in December 2025 to 1,144 in April 2026, while clinical hours increased from 75 to 624 over the same period. Each new payer relationship can potentially unlock access to one to two million or more covered lives.

The company is also advancing AI-enabled tools for patient intake, documentation, and follow-up that are designed to support physicians rather than replace them. These tools form part of the broader platform strategy and could drive further efficiency as volumes increase.

Broader Telehealth Sector Timing

The global telehealth market stood at US$186.41 billion in 2025 and is projected to reach US$1,272.81 billion by 2034 at a CAGR of 24.60%. North America accounted for roughly 45 percent of revenue in 2025. Reimbursement modernization, including new CMS billing codes, is making digital platforms more central to care delivery. Workers' compensation is emerging as a distinct growth channel, with the broader U.S. workers' compensation personal injury and PPO market expected to expand at a 5.4% CAGR from 2026 to 2033. Extended Medicare telehealth flexibilities through December 2027 provide additional regulatory runway.

Analyst Views and Valuation Context

¹Technical analyst Stewart Thomson issued a Strong Speculative Buy rating with price targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term. Fundamental Research Corp. reiterated a Buy rating and CA$1.55 target, citing intact growth trends supported by U.S. expansion and rising patient volumes.

Share Structure and Liquidity²

Rocket Doctor AI Inc. has a market cap of CA$60.62 million and 101.04 million shares outstanding. The 52-week range is CA$0.50 to CA$0.98. Management and insiders hold 4.24 percent of shares, with the remaining 95.76 percent held by retail investors.

Key Investor Takeaways

• The California network agreement provides diversified access to 60 million consumers across multiple reimbursement channels starting July 2026.
• Patient visit volumes in the U.S. grew sharply from 86 in December 2025 to 1,144 in April 2026, supported by expanding physician capacity.
• Expansion plans include Florida and Texas alongside continued California growth and additional payer relationships.
• AI tools for intake, documentation, and follow-up are positioned to improve provider efficiency without replacing physicians.
• Analysts maintain Buy or Strong Speculative Buy ratings with price targets ranging from CA$0.80 to CA$1.60.

Common Questions from Investors

Q: What does the new network agreement cover?
A: It covers primary care, complementary services, workers' compensation, auto medical, and Medicare Advantage through one national partner serving more than 700 health plans and approximately 60 million consumers.

Q: How fast is the telehealth market growing?
A: The market is projected to expand from US$186.41 billion in 2025 to US$1,272.81 billion by 2034 at a 24.60 percent CAGR.

Q: What are Rocket Doctor AI's near-term catalysts?
A: Continued U.S. state expansion, rising reimbursed patient volumes, and deployment of AI-enabled clinical tools.

Q: What are recent analyst ratings?
A: Recent ratings include a Strong Speculative Buy with targets up to CA$1.60 and a reiterated Buy with a CA$1.55 target.

The agreement marks a concrete step in Rocket Doctor AI's U.S. strategy and provides measurable scale through an established national network. Investors should monitor patient volume trends and additional state expansions for further evidence of execution.